Company news
Galectin Therapeutics Inc. (NASDAQ:GALT) news
Galectin Therapeutics Inc. news releases on 6ix. Latest, Apr 27, 2023: Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment…
Press releases — page 2
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023
April 26, 2023
Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases
April 17, 2023
Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update
March 29, 2023
Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
March 15, 2023
Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
March 1, 2023
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
January 23, 2023
Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
January 4, 2023
Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders
November 28, 2022
Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit
November 27, 2022
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update
November 13, 2022
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD
October 31, 2022
Galectin Therapeutics to Present in Upcoming Conferences
October 13, 2022
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer
October 11, 2022
Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
October 5, 2022
Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022
September 7, 2022
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update
August 14, 2022
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024
July 25, 2022
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022
June 20, 2022
Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
May 22, 2022
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
May 15, 2022
Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
April 13, 2022
Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update
March 30, 2022
Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 5, 2022
Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein
December 20, 2021
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
December 12, 2021
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update
November 14, 2021
UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
November 4, 2021
Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
October 26, 2021
UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
October 4, 2021
Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
October 4, 2021
Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein
September 20, 2021
Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 8, 2021
Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis
August 29, 2021
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update
August 15, 2021
Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer
July 8, 2021
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update
May 16, 2021
Galectin Therapeutics to Present at 4th Global NASH Congress
April 26, 2021
World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, Belapectin
April 18, 2021
Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy
April 12, 2021
Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study
April 5, 2021
Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update
March 30, 2021
OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy
March 7, 2021
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
March 3, 2021
Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
December 10, 2020
Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation
December 3, 2020
Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders
November 30, 2020
Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020
November 8, 2020
Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today
September 28, 2020
Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020
September 21, 2020
Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
September 9, 2020